Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
52-week open-label extension study of pimavanserin in adults and elderly with neuropsychiatric symptoms related to neurodegenerative disease
2017-004439-36Phase 3Completed
- Sponsor
- Acadia Pharmaceuticals
- Start
- Jun 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of pimavanserin in Neurodegenerative disorders (NDDs), sponsored by Acadia Pharmaceuticals. Primary endpoint: Treatment emergent adverse events (TEAEs). Started Jun 2018; status: completed.
02
Drugs
pimavanserin
03
Conditions
Neurodegenerative disorders (NDDs)
Beyond the preview
Go deeper on 2017-004439-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004439-36.